Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
Calbindin Study: Is Calcium the Molecular Handle on Dysfunction in AD?
21 July 2003. It’s getting hot around calcium. A trend is afoot about something going awry with calcium regulation in Alzheimer neurons, and it makes this ion an increasingly attractive suspect in AD pathogenesis, even if important details remain murky. The trend just got another lift with a PNAS paper from the laboratory of Lennart Mucke at the Gladstone Institute of Neurologic Diseases at the University of California, San Francisco. The scientists report that the behavioral deficits of APP-transgenic mice—held up as evidence that these models of β-amyloidosis indeed have “AD-like” symptoms, but also sometimes criticized for their fickleness and variability—correlate surprisingly tightly with calbindin, a calcium-binding protein that buffers intracellular calcium levels. Mucke’s team found a similar correlation with c-fos, a calcium-dependent immediate-early gene thought to play a role in synaptic function.

If replicated, this work could be relevant in several respects. First, it establishes a molecular link between Aβ generation and behavioral deficits, although the mechanism of calbindin and c-fos’ action in these mice (and in AD) remains unclear. Second, it extends other recent work distinguishing between small, nonfibrillar Aβ species and deposited plaques by implicating only the former. Third, it suggests that calbindin could serve as a new functional marker because its levels are tightly linked to cognitive decline.

This is not calbindin’s first appearance in AD research. Just recently, Changiz Geula reported a series of papers about calbindin, including one describing a selective and age-related loss of calbindin from cholinergic neurons in non-human primates (Wu et al., 2003">). Among prior studies on calbindin is one from Mark Mattson’s lab reporting that calbindin protects cultured cells against Aβ-induced toxicity (Guo et al., 1998). A more distantly related paper in last week’s Neuron connects the protein huntingtin to calcium signaling: see ARF related news story), again linking intracellular calcium and neurodegeneration. The present work demonstrates a cause-effect relationship between Aβ42 levels and age-dependent reduction of calbindin (and c-fos) in neurons key to learning and memory, and at the same time, it correlates these levels with the learning and memory deficits seen in APP-transgenic mice.

First author Jorge Palop and colleagues analyzed the expression of calbindin and c-fos in the hippocampus of PDAPP mice and in postmortem dentate gyrus tissue of humans with sporadic AD. They found that calbindin immunocytochemistry was markedly down in granule cells of the dentate gyrus. This reduction was region-specific as pyramidal cells in the nearby CA1 region were unaffected, and it did not reflect death of neurons but reduced levels in existing neurons. Calbindin expression in these neurons declined with advancing age and increasing Aβ levels. Calbindin levels appeared to be in lockstep with c-fos levels. Reductions in both these calcium-related proteins correlated with the relative abundance of Aβ42, but not with APP expression or plaque deposition.

Does this drop in calbindin and c-fos matter functionally? Water-maze tests indicated as much. Mice with the lowest calbindin/c-fos levels also had the greatest trouble with tasks requiring spatial learning and memory retention. General motor deficits did not account for the performance differences. This is the paper’s key finding. “Behavioral deficits in hAPP FAD mice showed a striking relationship to neuronal reductions of calbindin and c-fos in the dentate gyrus,” the authors write.

Though the prime focus in AD research has long been the loss of neurons in particular brain areas, more recent attention has grown for the question of what causes neuronal and/or synaptic dysfunction in still-living neurons, either before massive neuron loss occurs or in those neurons that somehow survive an ongoing disease process nearby. Perhaps, these authors suggest, calbindin and c-fos reductions are part of larger calcium-related changes that impair the function of these hardy neurons. This notion implies that neurons molecularly altered in this way could be ultimately be saved or treated.

The present study also carries further a line of investigation that tries to show that not just Aβ fibrils and mature plaques, but particularly small nonfibrillar assemblies of Aβ are damaging and, indeed, may be the ones that cause cognitive dysfunction. Specific mechanisms linking these assemblies to calbindin and other calcium-related changes are unknown; speculation includes changes in calcium-channel function, the formation of Aβ pores in membranes, and influences on inflammation, the authors write. Co-authors included others at the Gladstone Institute and Eliezer Masliah at the University of California, San Diego.

The scientists also suggest that the field pursue a potentially important practical outcome of this work. Since behavioral testing is laborious and can produce maddeningly variable results, other, simpler and more expedient outcome measures are needed to test experimental drugs in mouse models. The standard pathological marker in current use-plaque load-correlates poorly with behavioral changes, Palop et al. write. Calbindin levels correlate tightly and could become the basis for a better surrogate marker of neuronal dysfunction in the assessment of novel treatments, perhaps with biochemical or radiological methods.

In the present study, calbindin assessment in human tissue included 15 AD cases and two nondemented controls. Many more cases need to be analyzed before one can establish how well calbindin reductions correlate with cognitive deficits in AD, the authors note.-Gabrielle Strobel.

Reference:
Palop JJ, Jones B, Kekonius L, Chin J, Yu G-Q, Raber J, Masliah E, Mucke L. Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9572-7. Abstract

 
Comments on News and Primary Papers
  Comment by:  Vincent Marchesi, ARF Advisor
Submitted 21 July 2003  |  Permalink Posted 21 July 2003

Amyloid peptide-induced behavioral deficits in transgenic models of Alzheimer's disease are tightly linked to depletion of calcium-dependent proteins in granule cells of the dentate gyrus.

This work builds on earlier observations that described the reduction in levels of calbindin D28K, a high-affinity calcium-binding protein, in the brains of patients with various neurodegenerative diseases. Transgenic mice carrying mutant forms of human APP accumulate amyloid plaques and exhibit learning deficits. Careful immunochemical studies show that there are also significant reductions in the levels of calbindin D28K (CB) and c-Fos in the brains of these mice, and that these seem to correlate more with the levels of soluble Ab peptide levels in brain extracts than with the amount of accumulated amyloid plaque. Reduced levels of CB were also found in brain samples from patients with AD.

The strength of this study is the careful correlation of learning defects in genetically manipulated mice that show age-dependent changes in the amounts of a well-defined...  Read more


  Comment by:  Roland Pochet
Submitted 26 July 2003  |  Permalink Posted 3 August 2003
  I recommend the Primary Papers

I would like to stress that already in 1993, Sutherland MK, Wong L, Somerville MJ, Yoong LK, Bergeron C, Parmentier M, McLachlan DR published in Brain Res Mol Brain Res. 1993 Apr;18(1-2):32-42 Reduction of calbindin-28k mRNA levels in Alzheimer as compared to Huntington hippocampus. Indeed the correlation between learning deficit and calbinbin is indeed appealing and deserve further experiments. What about cross breeding knock out mice for calbindin and APP transgenic mice?

View all comments by Roland Pochet

  Comment by:  Wallace Dembski
Submitted 23 July 2003  |  Permalink Posted 3 August 2003
  I recommend the Primary Papers
  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad